The latest biotech news - Labiotech.eu

Home News and Trends Page 159

Latest Posts

parkinsons disease treefrog therapeutics cell therapy

News and Trends 9 Jun 2020

French Manufacturing Plant Launches to Make Cell Therapy Cheap and Scalable

The Bordeaux-based company Treefrog Therapeutics has opened an industrial demonstration plant with the aim of producing cell therapies 10 times more efficiently than with current technology. The €2M plant occupies an area around a fifth of the size of a football field and is expected to produce 80 billion cells per year when it reaches […]

June 9, 2020 - 4 minutesmins - By Jonathan Smith

epigenetics liquid biopsy base genomics

News and Trends 8 Jun 2020

UK Startup Launches with €10M to Detect Epigenetic Signs of Cancer in Blood

A seed round of €10.1M will fund the launch of the University of Oxford spinout Base Genomics, which aims to improve cancer detection by measuring epigenetic changes to tumor DNA circulating in the blood. The company’s oversubscribed seed funding round was led by Oxford Sciences Innovation, a local early-stage investment firm linked to the University […]

June 8, 2020 - 3 minutesmins - By David Kirk

inflammation nodthera

News and Trends 6 Jun 2020

Boost For Inflammatory Disease Biotech NodThera With €49M Series B

The UK-US biotech NodThera has raised €48.7M in Series B funding to progress its drug candidate through clinical trials for the treatment of inflammatory conditions such as inflammatory bowel disease. This round follows an impressive €32M Series A that Nodthera carried out in 2018. Danish firm Novo Ventures, part of the investment arm of Novo […]

June 6, 2020 - 3 minutesmins - By Helen Albert

genmab ipo nasdaq

News and Trends 5 Jun 2020

Upsized Nasdaq IPO Yields Calliditas €80M to Commercialize Kidney Drug

Swedish company Calliditas Therapeutics has raised an €80M IPO on the Nasdaq Global Select Market — 20% above its initial target — to fund an ongoing phase III trial of its lead candidate treatment for an inflammatory kidney condition. Calliditas plans to use the net proceeds together with its existing cash resources to fund an […]

June 5, 2020 - 2 minutesmins - By Laura Cowen

huntingtons disease dementia prilenia therapeutics

News and Trends 5 Jun 2020

Israeli-Dutch Biotech Raises €55M to Fight Huntington’s Disease and ALS

Prilenia Therapeutics has raised €55M in Series A funding to launch late-stage clinical trials of its small molecule candidate drug in Huntington’s disease and amyotrophic lateral sclerosis, incurable conditions that have very limited treatment options. Dutch life sciences VC Forbion led the round and was joined by new Chinese investor Morningside Venture Investments and the […]

June 5, 2020 - 3 minutesmins - By Helen Albert

kymab regeneron legal patent

News and Trends 4 Jun 2020

Update: Fifth US Antibody Patent Owned by UK Biotech Upheld in Regeneron Battle

Update (04/06/2020): After upholding four of Kymab’s patents addressing the production of antibody drugs earlier this year, the US Patent Trial and Appeal Board has rejected Regeneron’s attempt to invalidate a fifth patent regarding the same technology. So far, Regeneron has not requested a re-hearing from the Board regarding the decision to uphold Kymab’s first […]

June 4, 2020 - 4 minutesmins - By Anita Chakraverty

ADVERTISEMENT

more news cover2

News and Trends 3 Jun 2020

What Did European Oncology Players Offer at ASCO 2020?

Despite widespread clinical trial delays caused by the coronavirus pandemic, many oncology biotechs have been able to continue their fight against cancer. With advances in CAR T-cell therapies, cancer vaccines, RNA drugs, and more, European companies held a strong presence at the American Society of Clinical Oncology (ASCO) this year. The huge ASCO conference has […]

June 3, 2020 - 10 minutesmins - By Jonathan Smith

brain machine interface internet AI

News and Trends 29 May 2020

AI Drug Discovery Firm Exscientia Closes €54M Series C

UK-based Exscientia has closed a Series C financing round of €54M ($60M) to develop its artificial intelligence (AI) technology to guide drug discovery. The Danish investor Novo Holdings led the round with its first investment in the company. Additional funding also came from existing investors including drug development company Evotec and Chinese VC firm GT […]

May 29, 2020 - 3 minutesmins - By David Kirk

argenx myasthenia gravis efgartigimod

News and Trends 29 May 2020

Argenx Follows up Phase III Success with Giant €785M Global Offering

The Dutch biotech argenx has cashed in on recent positive phase III results by launching an enormous €784.7M ($862.5M) global share offering. Argenx’s fundraise swiftly follows the announcement of phase III trial results earlier this week, where its lead candidate antibody drug, efgartigimod, improved motor symptoms of patients with the chronic autoimmune disease myasthenia gravis. […]

May 29, 2020 - 2 minutesmins - By Jonathan Smith

central nervous system epilepsy parkinsons disease

News and Trends 29 May 2020

Spanish Neurology Biotech Launches with €7.6M Series A

Accure Therapeutics, a neurology biotech targeting central nervous system (CNS) conditions such as multiple sclerosis and Parkinson’s disease, has launched in Barcelona with a Series A of €7.6M. Alta Life Sciences, a life science venture capital firm based in the same city, and the Spanish governmental institution The Centre for Technological and Industrial Development funded […]

May 29, 2020 - 3 minutesmins - By Helen Albert

bladder cancer immunotherapy tollys

News and Trends 28 May 2020

French Startup Secures €2.3M to Advance Cancer RNA Immunotherapy

Lyon-based biopharmaceutical company Tollys has closed a Series A funding round of €2.3M to bring its lead RNA immunotherapy candidate to clinical trials in people with bladder cancer. The round was closed on the basis of the company reaching preclinical proof-of-concept for the drug. It brings the total amount raised by Tollys to €6.4M since […]

May 28, 2020 - 2 minutesmins - By Laura Cowen

covid 19 msd themis

News and Trends 28 May 2020

MSD Enters Covid-19 Vaccine Race by Acquiring Themis Bioscience

The US-based big pharma MSD has entered the race to be the first to develop an effective vaccine for Covid-19 by acquiring Austrian biotech Themis Bioscience and its vaccine technology for an undisclosed amount. MSD has been a bit slower than some of its contemporaries to announce its plans regarding a potential treatment or vaccine […]

May 28, 2020 - 3 minutesmins - By Helen Albert

ADVERTISEMENT